Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

Lead Sponsor:

Ocuphire Pharma, Inc.

Conditions:

Presbyopia

Eligibility:

All Genders

40-64 years

Phase:

PHASE2

Brief Summary

The objectives of this study are: To evaluate the efficacy of Nyxol + Pilocarpine to improve DCNVA in subjects with presbyopia

Eligibility Criteria

Inclusion

  • Males or females ≥ 40 and ≤ 64years of age.
  • BCDVA of 0.0 LogMAR(20/20 Snellen equivalent) or better in each eye under photopic conditions.
  • DCNVA of 0.4 LogMAR (20/50 Snellen equivalent) or worse under photopic conditions in each eye and binocularly.
  • Subjects who depend on reading glasses or bifocals in which their binocular best-corrected near VA is 0.1 LogMAR (20/25 Snellen equivalent) or better.

Exclusion

  • Ophthalmic (in either eye):
  • Use of any topical prescription or OTC ophthalmic medications of any kind within 7 days of Screening until study completion.
  • Use of any over-the-counter (OTC) artificial tears (preserved or unpreserved) at least once per day within 7 days of Screening until study completion.
  • Current use of any topical ophthalmic therapy for dry eye.
  • Tear break-up time of \< 5 seconds or corneal fluorescein staining.
  • Clinically significant ocular disease that might interfere with the study as deemed by the Investigator.
  • Recent or current evidence of ocular infection or inflammation in either eye.
  • Any history of herpes simplex or herpes zoster keratitis.
  • History of diabetic retinopathy or diabetic macular edema.
  • Known allergy, hypersensitivity, or contraindication to any component of the phentolamine, pilocarpine, or vehicle formulations.
  • History of cauterization of the punctum or punctal plug (silicone or collagen) insertion or removal.
  • Ocular trauma, ocular surgery, ocular laser treatment within the 6 months prior to Screening. Any subject with multifocal intraocular lenses are excluded.
  • History of any traumatic (surgical or nonsurgical) or non traumatic condition affecting the pupil or iris.
  • Unwilling or unable to discontinue use of contact lenses.
  • Conjunctival hyperemia ≥ grade 2 on the CCLRU 4-point scale.
  • Systemic:
  • Known hypersensitivity or contraindication to alpha- and/or beta adrenoceptor antagonists.
  • Known hypersensitivity or contraindication to any systemic cholinergic parasympathomimetic agents.
  • Clinically significant systemic disease that might interfere with the study as deemed by the Investigator.
  • Participation in any investigational study within 30 days prior to Screening.
  • Females of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.
  • Resting HR outside the specified range of 50 to 110 beats per minute.
  • Hypertension with resting diastolic BP \> 105 mmHg or systolic BP \> 160 mmHg.

Key Trial Info

Start Date :

February 15 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2021

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT04675151

Start Date

February 15 2021

End Date

June 30 2021

Last Update

October 10 2025

Active Locations (17)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (17 locations)

1

Clinical Site 12

Laguna Hills, California, United States, 92653

2

Clinical Site 6

Newport Beach, California, United States, 92663

3

Clinical Site 13

Crystal River, Florida, United States, 34461

4

Clinical Site 5

Longwood, Florida, United States, 32779